Detalles de la búsqueda
1.
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
N Engl J Med
; 2024 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38828951
2.
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Am J Hematol
; 99(3): 396-407, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38298023
3.
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
Am J Hematol
; 98(5): 730-738, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36869876
4.
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Am J Hematol
; 97(4): 481-490, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35089607
5.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(6): 801-812, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34087126
6.
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Br J Haematol
; 194(1): 120-131, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34036560
7.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34062004
8.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33755235
9.
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Br J Haematol
; 184(4): 536-546, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30460684
10.
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Ann Hematol
; 97(9): 1747, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29943159
11.
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Ann Hematol
; 97(9): 1671-1682, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29756171
12.
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Am J Hematol
; 98(1): E15-E19, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35604280
13.
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
Am J Hematol
; 98(9): E226-E229, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37340832
14.
Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply.
Lancet
; 397(10285): 1621-1623, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33933201
15.
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Eur J Haematol
; 99(5): 409-414, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28675766
16.
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Am J Hematol
; 97(3): E83-E86, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34882831
17.
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
Br J Haematol
; 194(4): 784-788, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34046887
18.
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Am J Hematol
; 96(10): E383-E386, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34161627
19.
Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
Eur J Haematol
; 92(4): 308-12, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24460646
20.
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Am J Hematol
; 89(8): 803-8, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24757085